TrialThe lancet. Gastroenterology & hepatology2023

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Rohit Loomba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.